Ideenat IDELALISIB 150mg Tablets

Get a Price/Quote

MOQ : 10 Packs

Ideenat IDELALISIB 150mg Tablets Specification

Indication
Chronic Lymphocytic Leukemia (CLL), Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma

Dosage Form
Tablet

Salt Composition
Idelalisib 150mg

Feature
Prescription-only targeted cancer therapy

Ingredients
Idelalisib

Application
Targeted therapy for hematological malignancies

Physical Color/Texture
White or off-white tablets

Storage Instructions
Store below 30C in a dry place, protect from light

Shelf Life
24 months from manufacturing

Route of Administration
Oral

Pack Size
30 tablets per box

Strength
150 mg

Country of Export
International (Canada, European Union, UK, USA, Australia)

Prescription/Non Prescription
Prescription

Ideenat IDELALISIB 150mg Tablets About

Experience the splendiferous innovation of Ideenat IDELALISIB 150mg Tablets, a prescription-only, praiseworthy targeted therapy meticulously crafted for Chronic Lymphocytic Leukemia, Follicular B-cell non-Hodgkin lymphoma, and Small lymphocytic lymphoma. Unlock laureate-worthy therapeutic results with each tablet containing the potent active salt, Idelalisib 150mg. Each international-grade box delivers 30 white or off-white tablets, ensuring optimal strength and efficacy. Manufactured in India, this special promotion centers on reliability, quality, and international standards. Store below 30C, protect from light, and benefit from a generous 24-month shelf life-an unparalleled solution for hematological malignancies.

Features, Usage & Applications of IDELALISIB 150mg Tablets

Ideenat IDELALISIB 150mg Tablets offer a splendiferous approach to targeted cancer therapy. Specially indicated for chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma, they are used as oral medications under strict prescription. The laureate formulation ensures praiseworthy outcomes for patients battling hematological malignancies. Convenient dosage form and strengths unlock optimal usage for tailored treatment regimens, contributing to improved patient management in oncologic clinical practices worldwide.

Fast Delivery, Strong Supply Ability & Global Market Reach

Through streamlined transport services, Ideenat IDELALISIB 150mg Tablets reach international export markets, including Canada, the European Union, the UK, USA, and Australia. The outlay for logistics is balanced by consistent supply ability, ensuring steady market value and credibility for manufacturers, suppliers, and traders from India. Products are shipped promptly to guarantee transit within industry-standard timeframes, supporting the medical sector with reliable delivery and access to prescription-only medications.

FAQ's of Ideenat IDELALISIB 150mg Tablets:

Q: How should Ideenat IDELALISIB 150mg Tablets be stored to maintain their efficacy?

A: It is essential to store Ideenat IDELALISIB 150mg Tablets below 30C in a dry place and protect them from light to preserve their quality and effectiveness.

Q: What are the main applications of Ideenat IDELALISIB 150mg Tablets?

A: These tablets are used as targeted therapy for hematological malignancies, specifically Chronic Lymphocytic Leukemia, Follicular B-cell non-Hodgkin lymphoma, and Small lymphocytic lymphoma.

Q: Where can Ideenat IDELALISIB 150mg Tablets be exported?

A: The tablets are exported internationally, with major markets including Canada, the European Union, the UK, USA, and Australia.

Q: What is the prescribed usage process for these tablets?

A: Ideenat IDELALISIB 150mg Tablets are taken orally as directed by a healthcare professional. The dosage and frequency depend on the specific medical condition and patient needs.

Q: When does the product expire and how long can it be stored?

A: The tablets have a shelf life of 24 months from the manufacturing date, provided they are stored as recommended.

Q: What benefits does IDELALISIB 150mg provide over traditional therapies?

A: As a prescription-only targeted treatment, IDELALISIB 150mg offers focused action against certain lymphoma types, potentially resulting in better tolerability and improved therapeutic outcomes compared to conventional chemotherapy.

Tell us about your requirement